Genmab A/S (NASDAQ:GMAB) announced that it will present pivotal new research from its late-stage oncology portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 30 to June 3 in Chicago. Key highlights include the first public results from a Phase 1/2 trial of rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate targeting folate receptor-alpha in patients with recurrent or advanced endometrial cancer, a disease with rising mortality and limited treatment options.Genmab A/S (NASDAQ:GMAB) Unveils Promising Rina-S and Epcoritamab Data at ASCO 2025

Genmab A/S (NASDAQ:GMAB) will also share long-term follow-up data from the Phase 1/2 EPCORE NHL-1 study of epcoritamab, a subcutaneously administered, T-cell–engaging bispecific antibody, focusing on adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who have maintained a complete response at two years.

Dr. Judith Klimovsky, Genmab A/S (NASDAQ:GMAB)’s Chief Development Officer, emphasized the company’s commitment to advancing antibody science for patients with few alternatives, particularly women with endometrial cancer. GMAB, in collaboration with ABBV, continues to investigate epcoritamab across multiple B-cell malignancies, with several Phase 3 trials ongoing. An investor webcast reviewing the Rina-S data will be held on June 2 during ASCO.

While we acknowledge the potential of GMAB to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk.  If you are looking for an AI stock that is more promising than GMAB and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.

Disclosure: None.

View Comments